Skip to content

Research on the effect of low-dose versus usual-dose oxytocin in preventing blood loss during cesarean delivery.

A randomized controlled, open-label, non-inferiority trial to compare the efficacy and safety of low-dose oxytocin versus standard-dose oxytocin in achieving adequate uterine tone and preventing postpartum haemorrhage during scheduled cesarean deliveries - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096393
Enrollment
150
Registered
2025-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O94-O9A- Other obstetric conditions, not elsewhere classified

Interventions

Intervention1: low dose oxytocin: 1 IU IV bolus over 1 minute after delivery of fetus, followed by maintenance infusion at 2.5–7.5 IU/hr (titrated hourly) for 4 hours using infusion pump. Rescue dose:

Sponsors

Postgraduate Institute of Medical Education and Research Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women aged 18–45 years 2. Singleton pregnancy 3. Scheduled cesarean delivery at 37–40 weeks 4. Regional anesthesia planned 5. Willing to participate and provide written informed consent

Exclusion criteria

Exclusion criteria: refusal to consent asa physical status more than 3 conditions increasing risk of uterine atony cardiac, hepatic,autoimmune,renal disorders uncontrolled hypertension, diabetes contraindications to regional anaesthesia cesarean performed during labor

Design outcomes

Primary

MeasureTime frame
adequate uterine tone on likert scale more than 2 at 5 minutes post oxytocin administrationTimepoint: 5 min

Secondary

MeasureTime frame
Total intraoperative blood loss 2. Change in hematocrit at 24 hours 3. Incidence of atonic postpartum haemorrhage 4. Requirement for additional uterotonics 5. Maternal haemodynamic changes (HR, BP) 6. Adverse drug reactions 7. Need for blood transfusionTimepoint: Up to 24 hours postoperative

Countries

India

Contacts

Public ContactDr kratika jha

Postgraduate Institute of Medical Education and Research, Chandigarh

aashicool84@gmail.com99155 01844

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026